Myocarditis and pericarditis associated with SARS-CoV-2 vaccines

Background: Estimates of the association between COVID-19 vaccines and myo-/pericarditis risk vary widely across studies due to scarcity of events, especially in age- and sex-stratified analyses. Methods: Population-based cohort study with nested self-controlled risk interval (SCRI) using healthcare...

Descripción completa

Detalles Bibliográficos
Autores: Bots, Sophie H.|||0000-0002-4483-5582, Riera Arnau, Judit|||0000-0001-7591-0218, Belitser, Svetlana V., Messina, Davide, Aragón, María|||0000-0002-5990-6953, Alsina, Ema, Douglas, Ian J., Durán, Carlos E.|||0000-0003-1853-3641, García-Poza, Patricia, Gini, Rosa, Herings, Ron M. C., Huerta, Consuelo|||0000-0003-4012-7826, Sisay, Malede Mequanent|||0000-0002-8546-0959, Martín-Pérez, Mar, Martin, Ivonne, Overbeek, Jetty A., Paoletti, Olga, Pallejà-Millán, Meritxell|||0000-0003-1985-8894, Schultze, Anna|||0000-0002-1637-837X, Souverein, Patrick|||0000-0002-7452-0477, Swart, Karin M. A., Villalobos, Felipe|||0000-0002-6907-8354, Klungel, Olaf H., Sturkenboom, Miriam|||0000-0003-1360-2388
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:281771
Acceso en línea:https://ddd.uab.cat/record/281771
https://dx.doi.org/urn:doi:10.3389/fphar.2022.1038043
Access Level:acceso abierto
Palabra clave:Myocarditis
Pericarditis
COVID-19 vaccine
Adverse drug reaction
Pharmacovigilance
id ES_b59d47ce9f7a09e55b5a2b16e33f315f
oai_identifier_str oai:ddd.uab.cat:281771
network_acronym_str ES
network_name_str España
repository_id_str
spelling Myocarditis and pericarditis associated with SARS-CoV-2 vaccinesA population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countriesBots, Sophie H.|||0000-0002-4483-5582Riera Arnau, Judit|||0000-0001-7591-0218Belitser, Svetlana V.Messina, DavideAragón, María|||0000-0002-5990-6953Alsina, EmaDouglas, Ian J.Durán, Carlos E.|||0000-0003-1853-3641García-Poza, PatriciaGini, RosaHerings, Ron M. C.Huerta, Consuelo|||0000-0003-4012-7826Sisay, Malede Mequanent|||0000-0002-8546-0959Martín-Pérez, MarMartin, IvonneOverbeek, Jetty A.Paoletti, OlgaPallejà-Millán, Meritxell|||0000-0003-1985-8894Schultze, Anna|||0000-0002-1637-837XSouverein, Patrick|||0000-0002-7452-0477Swart, Karin M. A.Villalobos, Felipe|||0000-0002-6907-8354Klungel, Olaf H.Sturkenboom, Miriam|||0000-0003-1360-2388MyocarditisPericarditisCOVID-19 vaccineAdverse drug reactionPharmacovigilanceBackground: Estimates of the association between COVID-19 vaccines and myo-/pericarditis risk vary widely across studies due to scarcity of events, especially in age- and sex-stratified analyses. Methods: Population-based cohort study with nested self-controlled risk interval (SCRI) using healthcare data from five European databases. Individuals were followed from 01/01/2020 until end of data availability (31/12/2021 latest). Outcome was first myo-/pericarditis diagnosis. Exposures were first and second dose of Pfizer, AstraZeneca, Moderna, and Janssen COVID-19 vaccines. Baseline incidence rates (IRs), and vaccine- and dose-specific IRs and rate differences were calculated from the cohort The SCRI calculated calendar time-adjusted IR ratios (IRR), using a 60-day pre-vaccination control period and dose-specific 28-day risk windows. IRRs were pooled using random effects meta-analysis. Findings: Over 35 million individuals (49·2% women, median age 39-49 years) were included, of which 57·4% received at least one COVID-19 vaccine dose. Baseline incidence of myocarditis was low. Myocarditis IRRs were elevated after vaccination in those aged < 30 years, after both Pfizer vaccine doses (IRR = 3·3, 95%CI 1·2-9.4; 7·8, 95%CI 2·6-23·5, respectively) and Moderna vaccine dose 2 (IRR = 6·1, 95%CI 1·1-33·5). An effect of AstraZeneca vaccine dose 2 could not be excluded (IRR = 2·42, 95%CI 0·96-6·07). Pericarditis was not associated with vaccination. Interpretation: mRNA-based COVID-19 vaccines and potentially AstraZeneca are associated with increased myocarditis risk in younger individuals, although absolute incidence remains low. More data on children (≤ 11 years) are needed.Universitat Autònoma de Barcelona 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/281771https://dx.doi.org/urn:doi:10.3389/fphar.2022.1038043reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2817712026-06-06T12:50:31Z
dc.title.none.fl_str_mv Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries
title Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
spellingShingle Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
Bots, Sophie H.|||0000-0002-4483-5582
Myocarditis
Pericarditis
COVID-19 vaccine
Adverse drug reaction
Pharmacovigilance
title_short Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
title_full Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
title_fullStr Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
title_full_unstemmed Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
title_sort Myocarditis and pericarditis associated with SARS-CoV-2 vaccines
dc.creator.none.fl_str_mv Bots, Sophie H.|||0000-0002-4483-5582
Riera Arnau, Judit|||0000-0001-7591-0218
Belitser, Svetlana V.
Messina, Davide
Aragón, María|||0000-0002-5990-6953
Alsina, Ema
Douglas, Ian J.
Durán, Carlos E.|||0000-0003-1853-3641
García-Poza, Patricia
Gini, Rosa
Herings, Ron M. C.
Huerta, Consuelo|||0000-0003-4012-7826
Sisay, Malede Mequanent|||0000-0002-8546-0959
Martín-Pérez, Mar
Martin, Ivonne
Overbeek, Jetty A.
Paoletti, Olga
Pallejà-Millán, Meritxell|||0000-0003-1985-8894
Schultze, Anna|||0000-0002-1637-837X
Souverein, Patrick|||0000-0002-7452-0477
Swart, Karin M. A.
Villalobos, Felipe|||0000-0002-6907-8354
Klungel, Olaf H.
Sturkenboom, Miriam|||0000-0003-1360-2388
author Bots, Sophie H.|||0000-0002-4483-5582
author_facet Bots, Sophie H.|||0000-0002-4483-5582
Riera Arnau, Judit|||0000-0001-7591-0218
Belitser, Svetlana V.
Messina, Davide
Aragón, María|||0000-0002-5990-6953
Alsina, Ema
Douglas, Ian J.
Durán, Carlos E.|||0000-0003-1853-3641
García-Poza, Patricia
Gini, Rosa
Herings, Ron M. C.
Huerta, Consuelo|||0000-0003-4012-7826
Sisay, Malede Mequanent|||0000-0002-8546-0959
Martín-Pérez, Mar
Martin, Ivonne
Overbeek, Jetty A.
Paoletti, Olga
Pallejà-Millán, Meritxell|||0000-0003-1985-8894
Schultze, Anna|||0000-0002-1637-837X
Souverein, Patrick|||0000-0002-7452-0477
Swart, Karin M. A.
Villalobos, Felipe|||0000-0002-6907-8354
Klungel, Olaf H.
Sturkenboom, Miriam|||0000-0003-1360-2388
author_role author
author2 Riera Arnau, Judit|||0000-0001-7591-0218
Belitser, Svetlana V.
Messina, Davide
Aragón, María|||0000-0002-5990-6953
Alsina, Ema
Douglas, Ian J.
Durán, Carlos E.|||0000-0003-1853-3641
García-Poza, Patricia
Gini, Rosa
Herings, Ron M. C.
Huerta, Consuelo|||0000-0003-4012-7826
Sisay, Malede Mequanent|||0000-0002-8546-0959
Martín-Pérez, Mar
Martin, Ivonne
Overbeek, Jetty A.
Paoletti, Olga
Pallejà-Millán, Meritxell|||0000-0003-1985-8894
Schultze, Anna|||0000-0002-1637-837X
Souverein, Patrick|||0000-0002-7452-0477
Swart, Karin M. A.
Villalobos, Felipe|||0000-0002-6907-8354
Klungel, Olaf H.
Sturkenboom, Miriam|||0000-0003-1360-2388
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Myocarditis
Pericarditis
COVID-19 vaccine
Adverse drug reaction
Pharmacovigilance
topic Myocarditis
Pericarditis
COVID-19 vaccine
Adverse drug reaction
Pharmacovigilance
description Background: Estimates of the association between COVID-19 vaccines and myo-/pericarditis risk vary widely across studies due to scarcity of events, especially in age- and sex-stratified analyses. Methods: Population-based cohort study with nested self-controlled risk interval (SCRI) using healthcare data from five European databases. Individuals were followed from 01/01/2020 until end of data availability (31/12/2021 latest). Outcome was first myo-/pericarditis diagnosis. Exposures were first and second dose of Pfizer, AstraZeneca, Moderna, and Janssen COVID-19 vaccines. Baseline incidence rates (IRs), and vaccine- and dose-specific IRs and rate differences were calculated from the cohort The SCRI calculated calendar time-adjusted IR ratios (IRR), using a 60-day pre-vaccination control period and dose-specific 28-day risk windows. IRRs were pooled using random effects meta-analysis. Findings: Over 35 million individuals (49·2% women, median age 39-49 years) were included, of which 57·4% received at least one COVID-19 vaccine dose. Baseline incidence of myocarditis was low. Myocarditis IRRs were elevated after vaccination in those aged < 30 years, after both Pfizer vaccine doses (IRR = 3·3, 95%CI 1·2-9.4; 7·8, 95%CI 2·6-23·5, respectively) and Moderna vaccine dose 2 (IRR = 6·1, 95%CI 1·1-33·5). An effect of AstraZeneca vaccine dose 2 could not be excluded (IRR = 2·42, 95%CI 0·96-6·07). Pericarditis was not associated with vaccination. Interpretation: mRNA-based COVID-19 vaccines and potentially AstraZeneca are associated with increased myocarditis risk in younger individuals, although absolute incidence remains low. More data on children (≤ 11 years) are needed.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/281771
https://dx.doi.org/urn:doi:10.3389/fphar.2022.1038043
url https://ddd.uab.cat/record/281771
https://dx.doi.org/urn:doi:10.3389/fphar.2022.1038043
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417378012463104
score 15,198674